Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in BJU Int

Retrieve available abstracts of 173 articles:
HTML format
Text format



Single Articles


    July 2017
  1. BASOURAKOS SP, Hoffman K, Kim J
    Active surveillance in prostate cancer: new efforts, new voices, new hope.
    BJU Int. 2017;120:4-5.
    PubMed     Text format    


    June 2017
  2. DE BRUYCKER A, Lambert B, Claeys T, Delrue L, et al
    Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy.
    BJU Int. 2017 Jun 24. doi: 10.1111/bju.13938.
    PubMed     Text format     Abstract available


  3. SOORIAKUMARAN P
    Testing Radical prostatectomy in men with prostate cancer and oligoMetastases to the bone: a randomised controlled feasibility trial.
    BJU Int. 2017 Jun 5. doi: 10.1111/bju.13925.
    PubMed     Text format     Abstract available


  4. TUMATI V, Jackson WC, Abugharib AE, Raj G, et al
    Natural History of 'Second' Biochemical Failure Following Salvage Radiation Therapy for Prostate Cancer: A Multi-Institution Study.
    BJU Int. 2017 Jun 5. doi: 10.1111/bju.13926.
    PubMed     Text format     Abstract available


    May 2017
  5. HEDDEN L, Wassersug R, Mahovlich S, Pollock P, et al
    Evaluating an educational intervention to alleviate distress amongst men with newly diagnosed prostate cancer and their partners.
    BJU Int. 2017 May 17. doi: 10.1111/bju.13885.
    PubMed     Text format     Abstract available


  6. CHIU PKF, Alberts AR, Venderbos LDF, Bangma CH, et al
    Additional benefit of using a risk based selection for prostate biopsy: an analysis of biopsy complications in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    BJU Int. 2017 May 12. doi: 10.1111/bju.13913.
    PubMed     Text format     Abstract available


  7. TOSOIAN JT, Chappidi MR, Bishoff JT, Freedland SJ, et al
    Prognostic Utility of Biopsy-Derived Cell Cycle Progression Score in Patients with NCCN Low-Risk Prostate Cancer Undergoing Radical Prostatectomy: Implications for Treatment Guidance.
    BJU Int. 2017 May 8. doi: 10.1111/bju.13911.
    PubMed     Text format     Abstract available


  8. ZUMSTEG ZS, Zelefsky MJ, Woo KM, Spratt DE, et al
    Unification of favorable intermediate, unfavorable intermediate, and very high risk-stratification criteria for prostate cancer.
    BJU Int. 2017 May 2. doi: 10.1111/bju.13903.
    PubMed     Text format     Abstract available


  9. GANDAGLIA G, Fossati N, Dell'Oglio P, Montorsi F, et al
    Is there a role for pure clinical prediction models in prostate cancer in the contemporary era?
    BJU Int. 2017;119:652-653.
    PubMed     Text format    


    April 2017
  10. PROTOPAPA E, van der Meulen J, Moore CM, Smith SC, et al
    Patient Reported Outcome (PRO) questionnaires for men who have radical surgery for prostate cancer: a conceptual review of existing instruments.
    BJU Int. 2017 Apr 24. doi: 10.1111/bju.13896.
    PubMed     Text format     Abstract available


  11. PARSONS JK, Pierce JP, Mohler J, Paskett E, et al
    The Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]): Recruitment Feasibility and Baseline Demographics of a Randomized Trial of Diet in Men on Active Surveillance for Prostate Cancer.
    BJU Int. 2017 Apr 24. doi: 10.1111/bju.13890.
    PubMed     Text format     Abstract available


  12. CHIEN GW, Slezak JM, Harrison TN, Jung H, et al
    Health-related quality of life outcomes from a contemporary prostate cancer registry in a large diverse population.
    BJU Int. 2017 Apr 19. doi: 10.1111/bju.13843.
    PubMed     Text format     Abstract available


  13. CRAWLEY D, Garmo H, Rudman S, Stattin P, et al
    Association between Type 2 diabetes, curative treatment and survival in men with intermediate and high risk localised prostate cancer.
    BJU Int. 2017 Apr 18. doi: 10.1111/bju.13880.
    PubMed     Text format     Abstract available


  14. VIOLET JA, Hofman MS
    Prostate specific membrane antigen (PSMA) from diagnostic to therapeutic target: radionuclide therapy comes of age in prostate cancer.
    BJU Int. 2017 Apr 5. doi: 10.1111/bju.13871.
    PubMed     Text format     Abstract available


  15. EMBERTON M
    An end to the phenomenon of 'upgrading' in early prostate cancer?
    BJU Int. 2017;119:506-507.
    PubMed     Text format    


    March 2017
  16. TELANG JM, Lane BR, Cher ML, Miller DC, et al
    Prostate cancer, family history, and eligibility for active surveillance: A systematic review of the literature.
    BJU Int. 2017 Mar 29. doi: 10.1111/bju.13862.
    PubMed     Text format     Abstract available


  17. DIJKSTRA S, Govers TM, Hendriks RJ, Schalken JA, et al
    Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
    BJU Int. 2017 Mar 29. doi: 10.1111/bju.13861.
    PubMed     Text format     Abstract available


  18. GROGAN J, Gupta R, Mahon KL, Stricker PD, et al
    Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in radical prostatectomy patients with long-term follow up.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13857.
    PubMed     Text format     Abstract available


  19. HOWARD LE, Moreira D, De Hoedt A, Aronson WJ, et al
    Cut-points for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13856.
    PubMed     Text format     Abstract available


  20. CLEMENT-ZHAO A, Auvray M, Aboudagga H, Blanc-Durand F, et al
    Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Mar 28. doi: 10.1111/bju.13855.
    PubMed     Text format     Abstract available


  21. MACLENNAN S, Williamson PR, Bekema H, Campbell M, et al
    A core outcome set for localised prostate cancer effectiveness trials.
    BJU Int. 2017 Mar 27. doi: 10.1111/bju.13854.
    PubMed     Text format     Abstract available


  22. KANDASWAMY GV, Bennett A, Narahari K, Hughes O, et al
    Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate risk localised prostate cancer - results from a large contemporaneous cohort.
    BJU Int. 2017 Mar 20. doi: 10.1111/bju.13850.
    PubMed     Text format     Abstract available


  23. KANTHABALAN A, Peters M, Van Vulpen M, McCartan N, et al
    Focal Salvage HIFU in radiorecurrent prostate cancer.
    BJU Int. 2017 Mar 4. doi: 10.1111/bju.13831.
    PubMed     Text format     Abstract available


  24. BALL MW, Harris KT, Schwen ZR, Mullins JK, et al
    Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series.
    BJU Int. 2017;119:444-448.
    PubMed     Text format     Abstract available


    February 2017
  25. SPAHN M, Morlacco A, Boxler S, Joniau S, et al
    Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: A multi-institutional study of 62 patients.
    BJU Int. 2017 Feb 20. doi: 10.1111/bju.13818.
    PubMed     Text format     Abstract available


  26. VAN LEEUWEN PJ, Hayen A, Thompson JE, Moses D, et al
    A Multiparametric Magnetic Resonance Imaging Based Risk Model to Determine the Risk of Significant Prostate Cancer prior to biopsy.
    BJU Int. 2017 Feb 16. doi: 10.1111/bju.13814.
    PubMed     Text format     Abstract available


  27. HAWKEN SR, Auffenberg GB, Miller DC, Lane BR, et al
    Calculating Life Expectancy to Inform Prostate Cancer Screening and Treatment Decisions.
    BJU Int. 2017 Feb 15. doi: 10.1111/bju.13812.
    PubMed     Text format     Abstract available


  28. VAN DER POEL HG, Wit EM, Acar C, van den Berg NS, et al
    Sentinel node biopsy for prostate cancer: report from a consensus panel meeting.
    BJU Int. 2017 Feb 10. doi: 10.1111/bju.13810.
    PubMed     Text format     Abstract available


  29. MURPHY DG, Hofman M, Lawrentschuk N, Maurer T, et al
    Bringing clarity or confusion? The role of prostate-specific membrane antigen positron-emission/computed tomography for primary staging in prostate cancer.
    BJU Int. 2017;119:194-195.
    PubMed     Text format    


  30. FICARRA V, Crestani A, Rossanese M, Palumbo V, et al
    Urethral-fixation technique improves early urinary continence recovery in patients who undergo retropubic radical prostatectomy.
    BJU Int. 2017;119:245-253.
    PubMed     Text format     Abstract available


  31. MATHIEU R, Lucca I, Vartolomei MD, Mbeutcha A, et al
    Role of survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study.
    BJU Int. 2017;119:234-238.
    PubMed     Text format     Abstract available


  32. WASHINO S, Okochi T, Saito K, Konishi T, et al
    Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients.
    BJU Int. 2017;119:225-233.
    PubMed     Text format     Abstract available


    January 2017
  33. MISRA-HEBERT AD, Hu B, Klein EA, Stephenson A, et al
    Prostate Cancer Screening Practices in a Large, Integrated Health System: 2007-2014.
    BJU Int. 2017 Jan 31. doi: 10.1111/bju.13793.
    PubMed     Text format     Abstract available


  34. SHIN T, Smyth TB, Ukimura O, Ahmadi N, et al
    Detection of Prostate Cancer Using Magnetic Resonance Imaging/Ultrasonography Fusion Targeted Biopsy in African-American Men.
    BJU Int. 2017 Jan 23. doi: 10.1111/bju.13786.
    PubMed     Text format     Abstract available


  35. PELLEGRINI KL, Sanda MG, Patil D, Long Q, et al
    Evaluation of a 24-Gene Signature for Prognosis of Metastatic Events and Prostate Cancer-Specific Mortality.
    BJU Int. 2017 Jan 20. doi: 10.1111/bju.13779.
    PubMed     Text format     Abstract available


  36. FAN L, Wang Y, Chenfei C, Pan J, et al
    Chromogranin A and neurone-specific enolase variations during the first three months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
    BJU Int. 2017 Jan 20. doi: 10.1111/bju.13781.
    PubMed     Text format     Abstract available


  37. TRABULSI EJ, Tripathi SK, Gomella L, Solomides C, et al
    Development of a Voided Urine Assay for Detecting Prostate Cancer Noninvasively: A Pilot Study.
    BJU Int. 2017 Jan 11. doi: 10.1111/bju.13775.
    PubMed     Text format     Abstract available


  38. CROUZET S, Blana A, Murat FJ, Pasticier G, et al
    Salvage high-intensity focused ultrasound (HIFU) for locally recurrent prostate cancer after failed radiation therapy: Multi-institutional analysis of 418 patients.
    BJU Int. 2017 Jan 7. doi: 10.1111/bju.13766.
    PubMed     Text format     Abstract available


  39. POORTHUIS MH, Vernooij RW, van Moorselaar RJ, de Reijke TM, et al
    First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of ten randomised clinical trials.
    BJU Int. 2017 Jan 6. doi: 10.1111/bju.13764.
    PubMed     Text format     Abstract available


  40. TOSOIAN JJ, Druskin SC, Andreas D, Mullane P, et al
    Prostate health index density improves detection of clinically-significant prostate cancer.
    BJU Int. 2017 Jan 6. doi: 10.1111/bju.13762.
    PubMed     Text format     Abstract available


  41. RESCIGNO P, Rodrigues DN, de Bono JS
    Circulating biomarkers of neuroendocrine prostate cancer: an unmet challenge.
    BJU Int. 2017;119:3-4.
    PubMed     Text format    


  42. SANTOK GD, Abdel Raheem A, Kim LH, Chang K, et al
    Perioperative and short-term outcomes of Retzius-sparing robot-assisted laparoscopic radical prostatectomy stratified by gland size.
    BJU Int. 2017;119:135-141.
    PubMed     Text format     Abstract available


  43. ZARGAR H, van den Bergh R, Moon D, Lawrentschuk N, et al
    The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
    BJU Int. 2017;119:110-115.
    PubMed     Text format     Abstract available


  44. DANNEMAN D, Drevin L, Delahunt B, Samaratunga H, et al
    Accuracy of prostate biopsies for predicting Gleason score in radical prostatectomy specimens: nationwide trends 2000-2012.
    BJU Int. 2017;119:50-56.
    PubMed     Text format     Abstract available


  45. PARK SY, Oh YT, Jung DC, Cho NH, et al
    Diffusion-weighted imaging predicts upgrading of Gleason score in biopsy-proven low grade prostate cancers.
    BJU Int. 2017;119:57-66.
    PubMed     Text format     Abstract available


    December 2016
  46. GHADJAR P, Hayoz S, Genitsch V, Zwahlen DR, et al
    Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer.
    BJU Int. 2016 Dec 17. doi: 10.1111/bju.13742.
    PubMed     Text format     Abstract available


  47. ALBISINNI S, Artigas C, Aoun F, Biaou I, et al
    Clinical impact of 68 Ga-PSMA PET/CT in prostate cancer patients with rising PSA after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
    BJU Int. 2016 Dec 15. doi: 10.1111/bju.13739.
    PubMed     Text format     Abstract available


  48. DE CASTRO ABREU AL, Fay CE, Park D, Quinn D, et al
    Robotic Salvage Retroperitoneal and Pelvic Lymph Node Dissection for "Node-only" Recurrent Prostate Cancer: Technique and Initial Series.
    BJU Int. 2016 Dec 15. doi: 10.1111/bju.13741.
    PubMed     Text format     Abstract available


  49. WANG LL, Wallis CJ, Sathianathen N, Lawrentschuk N, et al
    ProtecTion from overtreatment - does a randomised trial finally answer the key question in localised prostate cancer?
    BJU Int. 2016 Dec 8. doi: 10.1111/bju.13734.
    PubMed     Text format     Abstract available


    November 2016
  50. GNANAPRAGASAM VJ, Warren AY
    Improving clinical prognostic stratification models for men with prostate cancer: a practical step closer to more individualised care without added costs.
    BJU Int. 2016 Nov 22. doi: 10.1111/bju.13721.
    PubMed     Text format     Abstract available


  51. RAUSCHER I, Duwel C, Wirtz M, Schottelius M, et al
    Value of 111 In-PSMA-radioguided surgery for salvage lymphadenectomy in recurrent prostate cancer: correlation with histopathology and clinical follow-up.
    BJU Int. 2016 Nov 10. doi: 10.1111/bju.13713.
    PubMed     Text format     Abstract available


  52. HERDEN J, Heidenreich A, Weissbach L
    Risk Stratification - a Tool to predict the Course of Active Surveillance for Localized Prostate Cancer?
    BJU Int. 2016 Nov 10. doi: 10.1111/bju.13715.
    PubMed     Text format     Abstract available


  53. ESCH L, Fahlbusch M, Albers P, Hautzel H, et al
    11C-acetate PET/CT imaging for detection of recurrent disease following radical prostatectomy or radiotherapy in patients with prostate cancer.
    BJU Int. 2016 Nov 8. doi: 10.1111/bju.13706.
    PubMed     Text format     Abstract available


  54. POYET C, Hermanns T
    Prostate cancer risk calculators: still much work ahead.
    BJU Int. 2016;118:670-671.
    PubMed     Text format    


  55. ROCCO B, Boeri L
    Prostate cancer gene 3 assay in the magnetic resonance imaging (MRI)/ultrasonography fusion target biopsy era: a future to believe in.
    BJU Int. 2016;118:672-673.
    PubMed     Text format    


  56. DE LUCA S, Passera R, Cattaneo G, Manfredi M, et al
    High prostate cancer gene 3 (PCA3) scores are associated with elevated Prostate Imaging Reporting and Data System (PI-RADS) grade and biopsy Gleason score, at magnetic resonance imaging/ultrasonography fusion software-based targeted prostate biopsy af
    BJU Int. 2016;118:723-730.
    PubMed     Text format     Abstract available


    October 2016
  57. GILBERT DC, Duong T, Kynaston HG, Alhasso AA, et al
    Quality of life outcomes from the PATCH trial evaluating LHRH agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.
    BJU Int. 2016 Oct 18. doi: 10.1111/bju.13687.
    PubMed     Text format     Abstract available


  58. TILKI D, Preisser F, Tennstedt P, Tober P, et al
    Adjuvant radiation therapy is associated with better oncological outcome compared to salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy.
    BJU Int. 2016 Oct 15. doi: 10.1111/bju.13679.
    PubMed     Text format     Abstract available


  59. LOEB S, Shin SS, Broyles DL, Wei JT, et al
    Prostate Health Index (phi) Improves Multivariable Risk Prediction of Aggressive Prostate Cancer.
    BJU Int. 2016 Oct 15. doi: 10.1111/bju.13676.
    PubMed     Text format     Abstract available


  60. CORFIELD J, Crozier J, Joshua A, Bolton D, et al
    Understanding the role of new systemic agents in the treatment of prostate cancer.
    BJU Int. 2016 Oct 6. doi: 10.1111/bju.13633.
    PubMed     Text format     Abstract available


  61. COONEY KA, Beebe-Dimmer JL
    HOXB13 mutations and prostate cancer risk.
    BJU Int. 2016;118:496-7.
    PubMed     Text format    


  62. MEREDITH G, Wong D, Yaxley J, Coughlin G, et al
    The use of 68 Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer.
    BJU Int. 2016;118 Suppl 3:49-55.
    PubMed     Text format     Abstract available


  63. MATARAZA JM, Gotwals P
    Recent advances in immuno-oncology and its application to urological cancers.
    BJU Int. 2016;118:506-14.
    PubMed     Text format     Abstract available


  64. DEVECI S, Gotto GT, Alex B, O'Brien K, et al
    A survey of patient expectations regarding sexual function following radical prostatectomy.
    BJU Int. 2016;118:641-5.
    PubMed     Text format     Abstract available


  65. WYSOCK JS, Mendhiratta N, Zattoni F, Meng X, et al
    Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results.
    BJU Int. 2016;118:515-20.
    PubMed     Text format     Abstract available


  66. MURRAY NP, Aedo S, Reyes E, Orellana N, et al
    Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
    BJU Int. 2016;118:556-62.
    PubMed     Text format     Abstract available


    September 2016
  67. YAXLEY JW, Lah K, Yaxley JP, Gardiner RA, et al
    Long term outcome of high dose rate (HDR) brachytherapy for intermediate and high risk prostate cancer with a median follow up of 10 years.
    BJU Int. 2016 Sep 15. doi: 10.1111/bju.13659.
    PubMed     Text format     Abstract available


  68. HOFHEINZ RD, Lange C, Ecke T, Kloss S, et al
    Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional QoLiTime study.
    BJU Int. 2016 Sep 12. doi: 10.1111/bju.13658.
    PubMed     Text format     Abstract available


  69. BRANGER N, Maubon T, Traumann M, Thomassin-Piana J, et al
    Is a negative mpMRI really able to rule out significant prostate cancer?: The real life experience.
    BJU Int. 2016 Sep 12. doi: 10.1111/bju.13657.
    PubMed     Text format     Abstract available


  70. LOEB S, Curnyn C, Fagerlin A, Braithwaite RS, et al
    A Qualitative Study on Decision-Making by Prostate Cancer Physicians during Active Surveillance.
    BJU Int. 2016 Sep 9. doi: 10.1111/bju.13651.
    PubMed     Text format     Abstract available


  71. MARTORANA E, Pirola GM, Scialpi M, Micali S, et al
    Lesion volume predicts prostate cancer risk and aggressiveness: validation of its value alone and matched with PIRADS score.
    BJU Int. 2016 Sep 8. doi: 10.1111/bju.13649.
    PubMed     Text format     Abstract available


  72. EGEVAD L, Samaratunga H, Srigley JR, Delahunt B, et al
    Consensus guidelines for reporting prostate cancer Gleason Grade.
    BJU Int. 2016;118:E1-2.
    PubMed     Text format    


  73. JOHNSON MH
    Tailored prostate cancer survivorship: one size does not fit all.
    BJU Int. 2016;118:343-4.
    PubMed     Text format    


  74. EHDAIE B
    Active surveillance for prostate cancer: is it too active?
    BJU Int. 2016;118:343.
    PubMed     Text format    


    August 2016
  75. WILLIAMS SB, Chamie K, Duan Z, Hoffman KE, et al
    Risk of Hospitalization Following Primary Treatment for Prostate Cancer.
    BJU Int. 2016 Aug 25. doi: 10.1111/bju.13647.
    PubMed     Text format     Abstract available


  76. MCDANIEL AS, Ferraldeschi R, Krupa R, Landers M, et al
    Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer.
    BJU Int. 2016 Aug 18. doi: 10.1111/bju.13631.
    PubMed     Text format     Abstract available


  77. BECKMANN KR, O'Callaghan ME, Ruseckaite R, Kinnear N, et al
    Prostate cancer outcomes for men who present with symptoms at diagnosis.
    BJU Int. 2016 Aug 4. doi: 10.1111/bju.13622.
    PubMed     Text format     Abstract available


  78. HANSEN NL, Barrett T, Koo B, Doble A, et al
    The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting.
    BJU Int. 2016 Aug 4. doi: 10.1111/bju.13619.
    PubMed     Text format     Abstract available


  79. PATEL VR, Palayapalayam Ganapathi H
    Management dilemmas in low-risk prostate cancer.
    BJU Int. 2016;118:180-1.
    PubMed     Text format    


  80. FLAMIATOS JF, Beer TM, Graff JN, Eilers KM, et al
    COX-2 Inhibition for Prostate Cancer Chemoprevention: Double-Blind Randomized Study of Pre-Prostatectomy Celecoxib or Placebo.
    BJU Int. 2016 Aug 1. doi: 10.1111/bju.13612.
    PubMed     Text format     Abstract available



  81. Abstracts of the 17th Asia-Pacific Prostate Cancer Conference 2016, Australia, 31 August-3 September 2016.
    BJU Int. 2016;118 Suppl 1:6-42.
    PubMed     Text format    



  82. Welcome for APCC BJUi Supplement Embracing a precision approach to prostate cancer.
    BJU Int. 2016;118 Suppl 1:5.
    PubMed     Text format    


    July 2016
  83. MAYER EN, Tward JD, Bassett M, Lenherr SM, et al
    Management of Radiation Therapy Oncology Group (RTOG) grade 4 urinary adverse events (UAEs) from radiotherapy for prostate cancer.
    BJU Int. 2016 Jul 28. doi: 10.1111/bju.13607.
    PubMed     Text format     Abstract available


  84. EMERY JD, Jefford M, King M, Hayne D, et al
    The ProCare Trial: a phase II randomised controlled trial of shared care for follow-up of men with prostate cancer.
    BJU Int. 2016 Jul 19. doi: 10.1111/bju.13593.
    PubMed     Text format     Abstract available


  85. HEGEMANN M, Stenzl A, Bedke J, Chi KN, et al
    Liquid biopsy: ready to guide therapy in advanced prostate cancer?
    BJU Int. 2016 Jul 19. doi: 10.1111/bju.13586.
    PubMed     Text format     Abstract available


  86. LANE JA, Metcalfe C, Young GJ, Peters TJ, et al
    Patient-reported outcomes in the ProtecT randomised trial of clinically localised prostate cancer treatments: design and baseline urinary, bowel and sexual function and quality of life.
    BJU Int. 2016 Jul 14. doi: 10.1111/bju.13582.
    PubMed     Text format     Abstract available


  87. ZHANG BY, Riska SM, Mahoney DW, Costello BA, et al
    Germline Genetic Variation in JAK2 as a Prognostic Marker in Castration Resistant Prostate Cancer.
    BJU Int. 2016 Jul 13. doi: 10.1111/bju.13584.
    PubMed     Text format     Abstract available


  88. DEBRUYNE FM, Behre HM, Roehrborn CG, Maggi M, et al
    Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: Prostate health outcomes in the Registry of Hypogonadism in Men (RHYME).
    BJU Int. 2016 Jul 13. doi: 10.1111/bju.13578.
    PubMed     Text format     Abstract available


  89. LEYH-BANNURAH SR, Abou-Haidar H, Dell'Oglio P, Schiffmann J, et al
    Primary Gleason Pattern Upgrading in contemporary D'Amico low-risk prostate cancer patients: Implications for future biomarkers and imaging modalities.
    BJU Int. 2016 Jul 1. doi: 10.1111/bju.13570.
    PubMed     Text format     Abstract available


    June 2016
  90. ANDRONIS L, Goranitis I, Pirrie S, Pope A, et al
    Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
    BJU Int. 2016 Jun 3. doi: 10.1111/bju.13549.
    PubMed     Text format     Abstract available


  91. ZIETMAN A, Smith J, Klein E, Droller M, et al
    Consensus guidelines for reporting prostate cancer Gleason Grade.
    BJU Int. 2016;117:849.
    PubMed     Text format    


  92. ANDERSON CB, Tin AL, Sjoberg DD, Mulhall JP, et al
    Association between number of prostate biopsies and patient-reported functional outcomes after radical prostatectomy: implications for active surveillance protocols.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


  93. DE NUNZIO C, Presicce F, Lombardo R, Cancrini F, et al
    Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


  94. DINH KT, Mahal BA, Ziehr DR, Muralidhar V, et al
    Risk of prostate cancer mortality in men with a history of prior cancer.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


  95. WATSON E, Shinkins B, Frith E, Neal D, et al
    Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


    May 2016
  96. DE CARVALHO TM, Heijnsdijk EA, de Koning HJ
    Estimating the risks and benefits of Active Surveillance protocols for Prostate Cancer: A microsimulation study.
    BJU Int. 2016 May 25. doi: 10.1111/bju.13542.
    PubMed     Text format     Abstract available


  97. WINTER A, Sirri E, Jansen L, Wawroschek F, et al
    Comparison of prostate cancer survival in Germany and the United States: Can differences be attributed to differences in stage distributions?
    BJU Int. 2016 May 21. doi: 10.1111/bju.13537.
    PubMed     Text format     Abstract available


  98. VAN LEEUWEN PJ, Emmett L, Ho B, Delprado W, et al
    Prospective Evaluation of 68Gallium-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Prostate Cancer.
    BJU Int. 2016 May 21. doi: 10.1111/bju.13540.
    PubMed     Text format     Abstract available


  99. DURAND M, Jain M, Robinson B, Aronowitz E, et al
    Magnetic Resonance Microscopy May Enable Distinction Between Normal Histomorphological Features and Prostate Cancer in the Resected Prostate Gland.
    BJU Int. 2016 May 7. doi: 10.1111/bju.13523.
    PubMed     Text format     Abstract available


  100. RAISON N, Elhage O, Dasgupta P
    Getting Personal with Prostate Cancer: DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
    BJU Int. 2016 May 7. doi: 10.1111/bju.13522.
    PubMed     Text format     Abstract available


  101. PATEL U, Dasgupta P, Challacombe B, Cahill D, et al
    Pre-biopsy 3T MRI and targeted biopsy of the index prostate cancer - correlation with robot assisted radical prostatectomy.
    BJU Int. 2016 May 7. doi: 10.1111/bju.13525.
    PubMed     Text format     Abstract available


  102. GORIN MA, Pomper MG, Rowe SP
    PSMA-targeted imaging of prostate cancer: the best is yet to come.
    BJU Int. 2016;117:715-6.
    PubMed     Text format    


  103. CUSSANS A, Somani BK, Basarab A, Dudderidge TJ, et al
    The role of targeted prophylactic antimicrobial therapy before transrectal ultrasonography-guided prostate biopsy in reducing infection rates: a systematic review.
    BJU Int. 2016;117:725-31.
    PubMed     Text format     Abstract available


    April 2016
  104. FODOR A, Berardi G, Fiorino C, Picchio M, et al
    Toxicity and efficacy of salvage 11C-Choline PET/CT-guided radiation therapy in patients with prostate cancer lymph nodal recurrence.
    BJU Int. 2016 Apr 22. doi: 10.1111/bju.13510.
    PubMed     Text format     Abstract available


  105. BOKHORST LP, Zappa M, Carlsson SV, Kwiatkowski M, et al
    Correlation between stage shift and differences in mortality in the European Randomized study of Screening for Prostate Cancer (ERSPC).
    BJU Int. 2016 Apr 22. doi: 10.1111/bju.13505.
    PubMed     Text format     Abstract available


  106. WHITING PF, Moore TH, Jameson CM, Davies P, et al
    Symptomatic and quality of life outcomes following treatment for clinically localized prostate cancer: a systematic review.
    BJU Int. 2016 Apr 18. doi: 10.1111/bju.13499.
    PubMed     Text format     Abstract available


  107. SELKIRK CG, Helfand BT
    To PSA or not to PSA? Still a question for men with a family history of prostate cancer.
    BJU Int. 2016;117:545.
    PubMed     Text format    


  108. ERNSTMANN N, Weissbach L, Herden J, Winter N, et al
    Patient-physician-communication and health related quality of life of localized prostate cancer patients undergoing radical prostatectomy - a longitudinal multilevel analysis.
    BJU Int. 2016 Apr 1. doi: 10.1111/bju.13495.
    PubMed     Text format     Abstract available


  109. WONG LM, Tang V, Peters J, Costello A, et al
    Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort.
    BJU Int. 2016;117 Suppl 4:82-7.
    PubMed     Text format     Abstract available


  110. DELAHUNT B, Egevad L, Grignon DJ, Srigley JR, et al
    Prostate cancer grading: recent developments and future directions.
    BJU Int. 2016;117 Suppl 4:7-8.
    PubMed     Text format    


  111. LAWRENTSCHUK N
    PSA testing and early management of test-detected prostate cancer- consensus at last.
    BJU Int. 2016;117 Suppl 4:5-6.
    PubMed     Text format    


  112. RASTINEHAD AR, Durand M
    A comparison of magnetic resonance imaging and ultrasonography (MRI/US)-fusion guided prostate biopsy devices: too many uncontrolled variables.
    BJU Int. 2016;117:548-9.
    PubMed     Text format    


  113. CULIG Z
    New possibilities for urinary molecular diagnostics.
    BJU Int. 2016;117:547-8.
    PubMed     Text format    


  114. SUN M, Trinh QD
    A Surveillance, Epidemiology and End Results (SEER) database malfunction: perceptions, pitfalls and verities.
    BJU Int. 2016;117:551-2.
    PubMed     Text format    


  115. SELES M, Gutschi T, Mayrhofer K, Fischereder K, et al
    Sampling of the anterior apical region results in increased cancer detection and upgrading in transrectal repeat saturation biopsy of the prostate.
    BJU Int. 2016;117:592-7.
    PubMed     Text format     Abstract available


  116. KAMRAVA M, Hegde JV, Abgaryan N, Chang E, et al
    Does the addition of targeted prostate biopsies to standard systemic biopsies influence treatment management for radiation oncologists?
    BJU Int. 2016;117:584-91.
    PubMed     Text format     Abstract available


  117. ANG M, Rajcic B, Foreman D, Moretti K, et al
    Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
    BJU Int. 2016;117 Suppl 4:68-75.
    PubMed     Text format     Abstract available


  118. CHEN EC, Papa N, Lawrentschuk N, Bolton D, et al
    Incidence and risk factors of venous thromboembolism after pelvic uro-oncologic surgery--a single center experience.
    BJU Int. 2016;117 Suppl 4:50-3.
    PubMed     Text format     Abstract available


    March 2016
  119. HAGGSTROM C, Stattin P, Stocks T, Garmo H, et al
    Interpretation of conventional survival analysis and competing risk analysis: An example of hypertension and prostate cancer.
    BJU Int. 2016 Mar 31. doi: 10.1111/bju.13494.
    PubMed     Text format     Abstract available


  120. HECK MM, Thaler MA, Schmid SC, Seitz AK, et al
    Chromogranin A and neuron-specific enolase serum levels as predictors of treatment outcome in metastatic castration-resistant prostate cancer patients under abiraterone therapy.
    BJU Int. 2016 Mar 31. doi: 10.1111/bju.13493.
    PubMed     Text format     Abstract available


  121. SPRATT DE, Cole AI, Palapattu GS, Weizer AZ, et al
    Independent Surgical Validation of the New Prostate Cancer Grade Grouping System.
    BJU Int. 2016 Mar 24. doi: 10.1111/bju.13488.
    PubMed     Text format     Abstract available


  122. SHIOTA M, Yokomizo A, Takeuchi A, Kiyoshima K, et al
    Steroid co-introduction with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.
    BJU Int. 2016 Mar 17. doi: 10.1111/bju.13483.
    PubMed     Text format     Abstract available


  123. SHORE ND, Chu F, Moul J, Saltzstein D, et al
    ATRIGEL polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate levels of testosterone in four open label studies in advanced prostate cancer patients.
    BJU Int. 2016 Mar 17. doi: 10.1111/bju.13482.
    PubMed     Text format     Abstract available


  124. BORKOWETZ A, Platzek I, Toma M, Renner T, et al
    Direct comparison of multiparametric MRI and final histopathology in patients with proven prostate cancer in MRI/Ultrasound-fusion biopsy.
    BJU Int. 2016 Mar 2. doi: 10.1111/bju.13461.
    PubMed     Text format     Abstract available


  125. COLE AP, Leow JJ, Trinh QD
    New evidence from the Prostate Cancer Prevention Trial may exculpate cyclooxygenase (COX) blockers in erectile dysfunction.
    BJU Int. 2016;117:385-6.
    PubMed     Text format    


  126. LUNDON DJ
    Prostate cancer risk prediction and the persistence of uncertainty.
    BJU Int. 2016;117:382.
    PubMed     Text format    


  127. ROOBOL MJ
    Where we are with screening and risk prediction for prostate cancer in 2016.
    BJU Int. 2016;117:381.
    PubMed     Text format    


  128. LOEB S
    Prostate biopsy decisions: one-size-fits-all approach with total PSA is out and a multivariable approach with the Prostate Health Index is in.
    BJU Int. 2016;117:383.
    PubMed     Text format    


  129. NAMIKI S, Mitsuzuka K, Kaiho Y, Yamada S, et al
    Serum luteinizing hormone concentration is significantly associated with recovery of urinary function after radical prostatectomy.
    BJU Int. 2016;117:450-5.
    PubMed     Text format     Abstract available


  130. MAI Z, Yan W, Zhou Y, Zhou Z, et al
    Transperineal template-guided prostate biopsy: 10 years of experience.
    BJU Int. 2016;117:424-9.
    PubMed     Text format     Abstract available


    February 2016
  131. DE LA TAILLE A, Martinez-Pineiro L, Cabri P, Houchard A, et al
    Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen deprivation therapy.
    BJU Int. 2016 Feb 25. doi: 10.1111/bju.13455.
    PubMed     Text format     Abstract available


  132. VAN DIE MD, Bone KM, Emery J, Williams SG, et al
    Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials.
    BJU Int. 2016 Feb 22. doi: 10.1111/bju.13361.
    PubMed     Text format     Abstract available


  133. GOODALL PP, Little J, Robinson E, Trimble I, et al
    Initial experience of an algorithm-based protocol for the community follow-up of men with prostate cancer.
    BJU Int. 2016 Feb 15. doi: 10.1111/bju.13446.
    PubMed     Text format     Abstract available


  134. EVANS SM, Nag N, Roder D, Brooks A, et al
    Development of an International Prostate Cancer Outcomes Registry.
    BJU Int. 2016 Feb 15. doi: 10.1111/bju.13258.
    PubMed     Text format     Abstract available


  135. CARLSSON S, Jaderling F, Wallerstedt A, Nyberg T, et al
    Oncologic and functional outcomes one year after radical prostatectomy for very low risk prostate cancer. Results from the prospective LAPPRO trial.
    BJU Int. 2016 Feb 11. doi: 10.1111/bju.13444.
    PubMed     Text format     Abstract available


  136. JEFFERIES ER, Bahl A, Hounsome L, Eylert MF, et al
    Admissions to hospital due to fracture in England in prostate cancer patients treated with Androgen Deprivation Therapy (ADT) - do we have to worry about the hormones?
    BJU Int. 2016 Feb 6. doi: 10.1111/bju.13441.
    PubMed     Text format     Abstract available


  137. FOLEY RW, Maweni RM, Gorman L, Murphy K, et al
    The ERSPC Risk Calculators Significantly Outperform The PCPT 2.0 In The Prediction Of Prostate Cancer; A Multi-Institutional Study.
    BJU Int. 2016 Feb 2. doi: 10.1111/bju.13437.
    PubMed     Text format     Abstract available


  138. YAP SA
    Should we worry about positive surgical margins in prostate cancer?
    BJU Int. 2016;117:207-8.
    PubMed     Text format    


    January 2016
  139. RUDMAN SM, Gray KP, Batista JL, Pitt MJ, et al
    Risk of prostate cancer specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence.
    BJU Int. 2016 Jan 25. doi: 10.1111/bju.13428.
    PubMed     Text format     Abstract available


  140. MADAN RA, Karzai FH, Ning YM, Adesunloye BA, et al
    Phase II Trial of Docetaxel, Bevacizumab, Lenalidomide, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer.
    BJU Int. 2016 Jan 18. doi: 10.1111/bju.13412.
    PubMed     Text format     Abstract available


  141. BOYLE P, Koechlin A, Bota M, d'Onofrio A, et al
    Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate specific antigen (PSA): a meta-analysis.
    BJU Int. 2016 Jan 18. doi: 10.1111/bju.13417.
    PubMed     Text format     Abstract available


  142. STOREBJERG TM, Hoyer S, Kirkegaard P, Bro F, et al
    Prevalence of the HOXB13 G84E mutation in Danish men treated by radical prostatectomy and correlations with prostate cancer risk and aggressiveness.
    BJU Int. 2016 Jan 18. doi: 10.1111/bju.13416.
    PubMed     Text format     Abstract available


  143. BOKHORST LP, Lepisto I, Kakehi Y, Bangma CH, et al
    Complications after prostate biopsies in men on active surveillance and its effect on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study.
    BJU Int. 2016 Jan 14. doi: 10.1111/bju.13410.
    PubMed     Text format     Abstract available


  144. FREEDLAND SJ, Howard LE, Hanyok BT, Kadiyala VK, et al
    Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer.
    BJU Int. 2016 Jan 13. doi: 10.1111/bju.13405.
    PubMed     Text format     Abstract available


  145. VELTRI RW
    Serum marker %[-2]proPSA and the Prostate Health Index improve diagnostic accuracy for clinically relevant prostate cancer.
    BJU Int. 2016;117:12-13.
    PubMed     Text format    


  146. EMBERTON M
    Doubling our precision of risk stratification in early prostate cancer: too good to be true?
    BJU Int. 2016;117:8-9.
    PubMed     Text format    


  147. CHANDRASEKAR T, Evans CP
    Salvage radical prostatectomy: a few good men.
    BJU Int. 2016;117:9-10.
    PubMed     Text format    


  148. WILLIAMS SB, Bozkurt Y, Achim M, Achim G, et al
    Sequencing robot-assisted extended pelvic lymph node dissection prior to radical prostatectomy: a step-by-step guide to exposure and efficiency.
    BJU Int. 2016;117:192-8.
    PubMed     Text format     Abstract available


    December 2015
  149. GILSON C, Sydes MR, Chowdhury S
    Will chemotherapy change the management of prostate cancer?
    BJU Int. 2015 Dec 22. doi: 10.1111/bju.13400.
    PubMed     Text format     Abstract available


  150. VAN LEEUWEN PJ, Stricker P, Hruby G, Kneebone A, et al
    68Ga-PSMA has high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    BJU Int. 2015 Dec 18. doi: 10.1111/bju.13397.
    PubMed     Text format     Abstract available


  151. EMBERTON M
    Are men who are biopsied without prior prostate magnetic resonance imaging getting substandard care?
    BJU Int. 2015;116:837-9.
    PubMed     Text format    


  152. HANSKE J, Meyer CP, Trinh QD
    How can we improve surgical outcomes?
    BJU Int. 2015;116:835-6.
    PubMed     Text format    


  153. ALBERTSEN PC
    Surgery is possible: now let's prove its superior efficacy!
    BJU Int. 2015;116:834-5.
    PubMed     Text format    


  154. BAHL A, Masson S, Malik Z, Birtle AJ, et al
    Final quality of life and safety data for patients with metastatic castration-resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279).
    BJU Int. 2015;116:880-7.
    PubMed     Text format     Abstract available


  155. NOVARA G, Ficarra V, Zattoni F, Fedeli U, et al
    Recourse to radical prostatectomy and associated short-term outcomes in Italy: a country-wide study over the last decade.
    BJU Int. 2015;116:862-7.
    PubMed     Text format     Abstract available


  156. MONTORSI F, Gandaglia G, Briganti A
    Long-term outcomes of robot-assisted radical prostatectomy: Where do we stand?
    BJU Int. 2015;116:845-6.
    PubMed     Text format    


  157. SCHMID M, Ghani KR, Choueiri TK, Sood A, et al
    An evaluation of the 'weekend effect' in patients admitted with metastatic prostate cancer.
    BJU Int. 2015;116:911-9.
    PubMed     Text format     Abstract available


  158. TULIAO PH, Koo KC, Komninos C, Chang CH, et al
    Number of positive preoperative biopsy cores is a predictor of positive surgical margins (PSM) in small prostates after robot-assisted radical prostatectomy (RARP).
    BJU Int. 2015;116:897-904.
    PubMed     Text format     Abstract available


  159. MOORE CM, Azzouzi AR, Barret E, Villers A, et al
    Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
    BJU Int. 2015;116:888-96.
    PubMed     Text format     Abstract available


    November 2015
  160. ONG WL, Evans SM, Spelman T, Kearns PA, et al
    Comparison of oncological and health related quality of life (HRQOL) outcomes between open (ORP) and robotic-assisted radical prostatectomy (RARP) for localized prostate cancer - findings from the population-based Victorian Prostate Cancer Registry (P
    BJU Int. 2015 Nov 17. doi: 10.1111/bju.13380.
    PubMed     Text format     Abstract available


  161. ROLLE L, Falcone M, Ceruti C, Timpano M, et al
    A prospective multicentric international study on the surgical outcomes and patients' satisfaction rates of the "Sliding Technique" for end-stage Peyronie's disease with severe shortening of the penis and erectile dysfunction.
    BJU Int. 2015 Nov 11. doi: 10.1111/bju.13370.
    PubMed     Text format     Abstract available


  162. ALBERTSEN PC
    Does a positive margin always mandate adjuvant radiotherapy?
    BJU Int. 2015;116:677-8.
    PubMed     Text format    


  163. LOEB S, Ribal MJ
    Controversies in management of high-risk prostate and bladder cancer.
    BJU Int. 2015;116:675.
    PubMed     Text format    


  164. KUMAR A, Samavedi S, Bates AS, Coelho RF, et al
    Continence outcomes of robot-assisted radical prostatectomy in patients with adverse urinary continence risk factors.
    BJU Int. 2015;116:764-70.
    PubMed     Text format     Abstract available


  165. HSU CC, Paciorek AT, Cooperberg MR, Roach M 3rd, et al
    Postoperative radiation therapy for patients at high-risk of recurrence after radical prostatectomy: does timing matter?
    BJU Int. 2015;116:713-20.
    PubMed     Text format     Abstract available


  166. MELVIN JC, Garmo H, Daniel R, Shanmugalingam T, et al
    An investigation into the relationship between statins and cancer using population-based data.
    BJU Int. 2015;116:681-3.
    PubMed     Text format    


    October 2015
  167. MATSUSHITA K, Kent MT, Vickers AJ, von Bodman C, et al
    Preoperative predictive model of recovery of urinary continence after radical prostatectomy.
    BJU Int. 2015;116:577-83.
    PubMed     Text format     Abstract available


  168. SCOTT S, Samaratunga H, Chabert C, Breckenridge M, et al
    Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis.
    BJU Int. 2015;116 Suppl 3:26-30.
    PubMed     Text format     Abstract available


  169. MCCOMBIE SP, Hawks C, Emery JD, Hayne D, et al
    A 'One Stop' Prostate Clinic for rural and remote men: a report on the first 200 patients.
    BJU Int. 2015;116 Suppl 3:11-7.
    PubMed     Text format     Abstract available


  170. ROTH H, Millar JL, Cheng AC, Byrne A, et al
    The state of TRUS biopsy sepsis: readmissions to Victorian hospitals with TRUS biopsy-related infection over 5 years.
    BJU Int. 2015;116 Suppl 3:49-53.
    PubMed     Text format     Abstract available


  171. SUNDI D, Han M
    Brachytherapy for prostate cancer: feasible but oncological equivalence unproven.
    BJU Int. 2015;116 Suppl 3:89-91.
    PubMed     Text format    


    June 2015
  172. PARK J, Cho SY, Jeong SH, Lee SB, et al
    Low testosterone level is an independent risk factor for high-grade prostate cancer detection via biopsy.
    BJU Int. 2015 Jun 18. doi: 10.1111/bju.13206.
    PubMed     Text format     Abstract available


    May 2015
  173. CARLSSON S, Drevin L, Loeb S, Widmark A, et al
    Population-based study of long-term functional outcomes after prostate cancer treatment.
    BJU Int. 2015 May 8. doi: 10.1111/bju.13179.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: